AbbVie to Acquire Apogee Therapeutics for $10.9B (opens in new tab)

Apogee’s lead candidate zumilokibart, an IL-13 inhibitor also called APG777, is a long-acting treatment that, according to the company, holds “pipeline-in-a-product potential” because of the opportunity it has for treating a variety of immunology and inflammation (I&I) diseases for which the drug is under study. The post appeared first on .